CD24+ Liver Tumor-Initiating Cells Drive Self-Renewal and Tumor Initiation through STAT3-Mediated NANOG Regulation

被引:569
作者
Lee, Terence Kin Wah [1 ,2 ]
Castilho, Antonia [1 ,2 ]
Cheung, Vincent Chi Ho [1 ,2 ]
Tang, Kwan Ho [2 ]
Ma, Stephanie [1 ,2 ]
Irene Oi Lin Ng [1 ,2 ]
机构
[1] Univ Hong Kong, State Key Lab Liver Res, Pokfulam, Hong Kong, Peoples R China
[2] Univ Hong Kong, Liver Canc & Hepatitis Res Lab, Dept Pathol, Li Ka Shing Fac Med, Pokfulam, Hong Kong, Peoples R China
关键词
CANCER STEM-CELLS; HEPATOCELLULAR-CARCINOMA; PROSPECTIVE IDENTIFICATION; TGF-BETA; EXPRESSION; GENE; RECURRENCE; MODELS;
D O I
10.1016/j.stem.2011.06.005
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Tumor-initiating cells (T-ICs) are a subpopulation of chemoresistant tumor cells that have been shown to cause tumor recurrence upon chemotherapy. Identification of T-ICs and their related pathways are therefore priorities for the development of new therapeutic paradigms. We established chemoresistant hepatocellular carcinoma (HCC) xenograft tumors in immunocompromised mice in which an enriched T-IC population was capable of tumor initiation and self-renewal. With this model, we found CD24 to be upregulated in residual chemoresistant tumors when compared with bulk tumor upon cisplatin treatment. CD24(+) HCC cells were found to be critical for the maintenance, self-renewal, differentiation, and metastasis of tumors and to significantly impact patients' clinical outcome. With a lentiviral-based knockdown approach, CD24 was found to be a functional liver T-IC marker that drives T-IC genesis through STAT3-mediated NANOG regulation. Our findings point to a CD24 cascade in liver T-ICs that may provide an attractive therapeutic target for HCC patients.
引用
收藏
页码:50 / 63
页数:14
相关论文
共 52 条
[1]   Nonsurgical treatment of hepatocellular carcinoma [J].
Aguayo, A ;
Patt, YZ .
SEMINARS IN ONCOLOGY, 2001, 28 (05) :503-513
[2]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[3]  
Al-Hajj M, 2007, CURR OPIN ONCOL, V19, P61
[4]  
ARII S, 1992, CANCER, V69, P913, DOI 10.1002/1097-0142(19920215)69:4<913::AID-CNCR2820690413>3.0.CO
[5]  
2-T
[6]  
Averbook BJ, 2002, SURGERY, V132, P611
[7]   Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment [J].
Bertolini, Giulia ;
Roz, Luca ;
Perego, Paola ;
Tortoreto, Monica ;
Fontanella, Enrico ;
Gatti, Laura ;
Pratesi, Graziella ;
Fabbri, Alessandra ;
Andriani, Francesca ;
Tinelli, Stella ;
Roz, Elena ;
Caserini, Roberto ;
Lo Vullo, Salvatore ;
Camerini, Tiziana ;
Mariani, Luigi ;
Delia, Domenico ;
Calabro, Elisa ;
Pastorino, Ugo ;
Sozzi, Gabriella .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (38) :16281-16286
[8]   Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer [J].
Byers, Lauren Averett ;
Sen, Banibrata ;
Saigal, Babita ;
Diao, Lixia ;
Wang, Jing ;
Nanjundan, Meera ;
Cascone, Tina ;
Mills, Gordon B. ;
Heymach, John V. ;
Johnson, Faye M. .
CLINICAL CANCER RESEARCH, 2009, 15 (22) :6852-6861
[9]   Hepatocellular carcinoma: Current management and future trends [J].
Carr, BI .
GASTROENTEROLOGY, 2004, 127 (05) :S218-S224
[10]   Prospective identification of tumorigenic prostate cancer stem cells [J].
Collins, AT ;
Berry, PA ;
Hyde, C ;
Stower, MJ ;
Maitland, NJ .
CANCER RESEARCH, 2005, 65 (23) :10946-10951